Pharmaceutical composition for treating Parkinson's disease

The combination of compound (I) with dopamine replacement therapy improved motor symptoms of Parkinson's disease, addressing the inadequacy of existing therapies and motor complications, and achieving better treatment outcomes.

CN118946348APending Publication Date: 2024-11-12EISAI R&D MANAGEMENT CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031557.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-27
Filing Date
2023-04-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing dopamine replacement therapy is not effective enough in treating Parkinson's disease, especially in motor symptoms, and long-term use may lead to motor complications, such as loss of efficacy.

Method used

Compound (I) is used in combination with dopamine replacement therapy agents, such as levodopa, through different administration methods, such as simultaneous, separate or time-interval administration, to improve the symptoms of Parkinson's disease.

Benefits of technology

The combination of compound (I) with dopamine replacement therapy significantly improved motor symptoms of Parkinson's disease, reduced the exacerbation of motor complications, and was more effective than dopamine replacement therapy alone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946348A_ABST
    Figure CN118946348A_ABST
Patent Text Reader

Abstract

Disclosed is a pharmaceutical composition for the treatment of Parkinson's disease, which comprises N-[(1S)-2, 2, 5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl] sulfonamide represented by formula (I) or a pharmaceutically acceptable salt of the N-[(1S)-2, 2, 5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl] sulfonamide. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to a pharmaceutical composition for treating Parkinson's disease. Background Art

[0002] Parkinson's disease is a neurodegenerative disease caused by selective damage to dopaminergic neurons in the substantia nigra. Parkinson's patients experience progressive motor symptoms and non-motor symptoms, both of which greatly impair the patient's quality of life (QOL). As motor symptoms, in the early stage of the disease, bradykinesia, tremor, difficulty walking, dysphonia, rigidity, weakness, loss of facial expression, postural deformity, etc., will occur; in the late stage of Parkinson's disease, movement disorders, motor fluctuations, freezing gait, falls, etc. will occur. As non-motor symptoms, olfactory disorders, sleep disorders, constipation, erectile dysfunction, etc. will occur (Non-Patent Literature 1).

[0003] The treatment basis of Parkinson's disease is a drug therapy centered on dopamine replacement therapy, including the use of dopamine precursor levodopa (L-dopa). Although levodopa is used as the main drug of dopamine replacement therapy, it is known that its therapeutic effect on some motor symptoms is insufficient, and it is also known that along with long-term medication or disease progression, motor complications such as movement disorders and disappearance of drug efficacy can be produced. Levodopa, in addition to being used alone, can also be used in combination with dopa decarboxylase inhibitors such as carbidopa or benserazide, dopamine receptor agonists, monoamine oxidase (MAOB) inhibitors, entacapone and other catechol-O-methyltransferase (COMT) inhibitors (non-patent literature 1 and 2).

[0004] GABA is the main inhibitory neurotransmitter in the central nervous system. GABA released into the synaptic cleft acts on GABA A GABA receptors B Receptor, and then taken up by presynaptic cells etc. through GABA transporter (GAT). It is reported that GAT-1, a subtype of GAT, is correlated with Parkinson's disease. According to non-patent literature 3, in a mouse model of early Parkinson's syndrome, GAT-1 is downregulated to enhance the tonic GABAergic inhibition of dopamine release, and the nigrostriatal co-release of GABA is weakened. According to non-patent literature 4, in a rat model of Parkinson's disease, blocking GAT-1 in the lateral habenula improves depression-like behavior, and the blockade does not affect voluntary movement. According to non-patent literature 5, treatment before the onset of Parkinson's disease with the GAT-1 inhibitor tiagabine weakens the activation of microglia, and locally protects nigrostriatal axons in a mouse model of Parkinson's disease to improve motor dysfunction.

[0005] It has been reported that N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfonamide represented by formula (I) (hereinafter also referred to as "compound (I)") has a seizure suppressive effect in a mouse kindling model (EDS) as an epilepsy model. 50 ) and neurotoxicity in the rotarod test (TD 50 ) compared with the calculated treatment coefficient (TD 50 / ED 50 ) is higher than the control compound, and has the applicability as a safer epilepsy therapeutic agent (Patent Document 1). It is reported that compound (I) exhibits analgesic effects in various animal models and has the applicability as a therapeutic and / or preventive agent for pain (Patent Document 2). In addition, it is also reported that the combination of compound (I) and AMPA-type glutamate receptor antagonists is expected to provide a safe and effective drug therapy for all epilepsy cases (Patent Document 3). However, the relationship between compound (I) and the treatment of Parkinson's disease has not been reported.

[0006]

[0007] Reference List

[0008] Patent Literature

[0009] Patent Document 1: U.S. Patent No. 9018260

[0010] Patent Document 2: U.S. Patent No. 9610262

[0011] Patent Document 3: U.S. Patent Application Publication No. 2021 / 000771

[0012] Patent Document 4: WO 2003 / 063876

[0013] Non-patent literature

[0014] Non-patent literature 1: Lee et al,"A review on Parkinson's disease treatment", Neuroimmunol. Neuroinflammation, 2021, 8: 222-44.

[0015] Non-patent literature 2: Bastiaan R. Bloem et al, "Parkinson's disease", Lancet, 2021, 397: 2284-303.

[0016] Non-patent document 3: Roberts et al, "GABA uptake transporters support dopaminerelease in dorsal striatum with maladaptive downregulation in a parkinsonismmodel", Nature Communications, 2020, 11: 4958.

[0017] Non-patent document 4: Lyu et al, "Blockade of GABA transporter-1and GABAtransporter-3 in the lateral habenula improves depressive-like behaviors in arat model of Parkinson's disease", Neuropharmacology, 2020, 181: 108369.

[0018] Non-patent document 5: Liu et al, "Tiagabine Protects Dopaminergic Neuronsagainst Neurotoxins by Inhibiting Microglial Activation", Scientific Reports, 2015, 5: 15720. Summary of the invention

[0019] Technical issues

[0020] The object of the present invention is to provide a pharmaceutical composition for treating Parkinson's disease.

[0021] Solution to the problem

[0022] The inventors of the present invention have conducted intensive research to achieve the above-mentioned objectives and have found that compound (I) improves the symptoms of Parkinson's disease, especially motor symptoms, in a primate model of Parkinson's disease. It has also been found that the combination of compound (I) and a dopamine replacement therapeutic agent is also effective in improving the symptoms of Parkinson's disease, especially motor symptoms.

[0023] That is, this disclosure relates to the following <1> to <27> .

[0024] <1> A pharmaceutical composition for treating Parkinson's disease, comprising compound (I):

[0025]

[0026] or a pharmaceutically acceptable salt thereof.

[0027] <2> according to <1> The pharmaceutical composition comprises compound (I) or a pharmaceutically acceptable salt thereof, wherein the composition is administered in combination with a dopamine replacement therapeutic agent.

[0028] <3> according to <2> The pharmaceutical composition, wherein the dopamine replacement therapeutic agent comprises levodopa.

[0029] <3-1> According to <2> or <3> The pharmaceutical composition, wherein the dopamine replacement therapeutic agent and the compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0030] <4> A pharmaceutical composition for treating Parkinson's disease, comprising levodopa, wherein the composition is administered in combination with compound (I) or a pharmaceutically acceptable salt thereof.

[0031] <4-1> Based on <4> The pharmaceutical composition, wherein the levodopa and compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0032] <5> according to <1> The pharmaceutical composition according to any one of <4-1> to <4-1>, wherein the composition is used to treat motor symptoms of Parkinson's disease.

[0033] <6> A method for treating Parkinson's disease, comprising administering compound (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.

[0034] <7> according to <6> The method further comprises administering a dopamine replacement therapeutic agent.

[0035] <8> according to <7> The method described herein, wherein the dopamine replacement therapeutic agent comprises levodopa.

[0036] <8-1> According to <7> or <8> The method, wherein the dopamine replacement therapeutic agent and compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0037] <9> according to <6> The method according to any one of <8-1> to <8-1>, wherein the method is used to treat the motor symptoms of Parkinson's disease.

[0038] <10> A therapeutic agent for Parkinson's disease, comprising compound (I) or a pharmaceutically acceptable salt thereof.

[0039] <11> according to <10> The therapeutic agent comprises compound (I) or a pharmaceutically acceptable salt thereof, wherein the agent is administered in combination with a dopamine replacement therapeutic agent.

[0040] <12> according to <11> The therapeutic agent, wherein the dopamine replacement therapeutic agent comprises levodopa.

[0041] <12-1> According to <11> or <12> The therapeutic agent, wherein the dopamine replacement therapeutic agent and compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0042] <13> A therapeutic agent for Parkinson's disease, comprising levodopa, wherein the agent is administered in combination with compound (I) or a pharmaceutically acceptable salt thereof.

[0043] <13-1> According to <13> The therapeutic agent, wherein levodopa and the compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0044] <14> according to <10> The therapeutic agent according to any one of <13-1>, which is used for treating motor symptoms of Parkinson's disease.

[0045] <15> Use of compound (I) or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for Parkinson's disease.

[0046] <16> according to <15> The use described herein, wherein the therapeutic agent for Parkinson's disease is administered in combination with a dopamine replacement therapeutic agent.

[0047] <17> according to <16> The use described herein, wherein the dopamine replacement therapeutic agent comprises levodopa.

[0048] <17-1> According to <16> or <17> The use described above, wherein the dopamine replacement therapeutic agent and the compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0049] <18> Use of levodopa for the manufacture of a therapeutic agent for Parkinson's disease to be administered in combination with compound (I) or a pharmaceutically acceptable salt thereof.

[0050] <18-1> According to <18> The use described above, wherein levodopa and compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0051] <19> according to <15> The use according to any one of <18-1> to <18-1>, which is used to treat the motor symptoms of Parkinson's disease.

[0052] <20> A compound (I) or a pharmaceutically acceptable salt thereof, for use in treating Parkinson's disease.

[0053] <21> according to <20> The compound or its salt, wherein the compound or its salt is administered in combination with a dopamine replacement therapeutic agent.

[0054] <22> according to <21> The compound or salt thereof, wherein the dopamine replacement therapeutic agent comprises levodopa.

[0055] <23> according to <21> or <22> The compound (I) or a pharmaceutically acceptable salt thereof, wherein the dopamine replacement therapeutic agent and the compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at a certain time interval.

[0056] <24> according to <20> or <23> The compound (I) or a pharmaceutically acceptable salt thereof described in any one of the preceding claims, wherein the compound (I) or a pharmaceutically acceptable salt thereof is used for treating the motor symptoms of Parkinson's disease.

[0057] <25> A dopamine replacement therapeutic agent for use in treating Parkinson's disease, wherein the agent is administered in combination with compound (I) or a pharmaceutically acceptable salt thereof.

[0058] <25-1> According to <25> The dopamine replacement therapeutic agent comprises levodopa.

[0059] <25-2> According to <25> Or the dopamine replacement therapy agent described in <25-1>, wherein the dopamine replacement therapy agent and compound (I) or a pharmaceutically acceptable salt thereof are administered simultaneously, separately, continuously or at certain time intervals.

[0060] <26> according to <25> The dopamine replacement therapeutic agent according to any one of <25-2>, which is used for treating motor symptoms of Parkinson's disease.

[0061] <27> A combination of a dopamine replacement therapeutic agent and compound (I) or a pharmaceutically acceptable salt thereof, for use in treating Parkinson's disease.

[0062] Advantageous Effects of the Invention

[0063] The pharmaceutical composition for treating Parkinson's disease of the present invention is applicable in treating Parkinson's disease, for example, improving motor symptoms. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 : is a graph showing the total score result of NDS (neurological deficit score) in Test Example 1.

[0065] Figure 2 is a diagram showing the scoring results of general behaviors in Test Example 1.

[0066] Figure 3 is a diagram showing the scoring results of the specific motor function in Test Example 1.

[0067] Figure 4 is a graph showing the tremor score results in Test Example 1.

[0068] Figure 5 is a diagram showing the total score result of NDS in Test Example 2.

[0069] Figure 6 is a diagram showing the scoring results of general behaviors in Test Example 2.

[0070] Figure 7 is a diagram showing the scoring results of the specific motor function in Test Example 2.

[0071] Figure 8 is a graph showing the tremor score results in Test Example 2.

[0072] Fig. 9 is a graph showing the dyskinesia scoring results in Test Example 3. DETAILED DESCRIPTION

[0073] The contents of the present disclosure will be described in detail below.

[0074] N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfonamide is a compound represented by the following formula (I).

[0075]

[0076] For example, Compound (I) or a pharmaceutically acceptable salt thereof can be produced by the method described in Patent Document 1.

[0077] The "pharmaceutically acceptable salt" is not particularly limited as long as the salt is formed by Compound (I) and another substance. For example, the pharmaceutically acceptable salt may be an acid addition salt such as an inorganic acid salt, an organic acid salt, an acidic amino acid salt, or the like.

[0078] Examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Examples of salts with organic acids include salts with acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, etc.

[0079] Examples of the salt with an acidic amino acid include salts with aspartic acid, glutamic acid and the like.

[0080] The pharmaceutical composition for treating Parkinson's disease disclosed herein can be produced by mixing a pharmaceutically acceptable additive with compound (I) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition for treating Parkinson's disease disclosed herein can be produced, for example, according to known methods such as the method described in the general rules for preparations of the 18th revised edition of the Japanese Pharmacopoeia.

[0081] The pharmaceutical composition for treating Parkinson's disease of the present disclosure can be appropriately administered to patients according to its dosage form.

[0082] The pharmaceutical composition for treating Parkinson's disease disclosed herein can be administered orally in the form of solid preparations such as tablets, granules, fine granules, powders or capsules, solutions, gels, syrups, etc. The pharmaceutical composition can be administered parenterally in the form of injections, suppositories, ointments, dressings, etc.

[0083] When a solid preparation is produced, the preparation can be produced by (i) adding an excipient and, if necessary, a binder, a disintegrant, a lubricant, a colorant, a flavoring agent, etc. as additives to a salt of compound (I) or a crystal thereof, and then (ii) forming a tablet, granule, fine granule, powder, capsule, etc. by a common method. The above additives can be appropriately combined for preparation. Tablets, granules, etc. can be coated as needed.

[0084] Examples of the excipient include lactose, sucrose, glucose, corn starch, mannitol, sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, calcium hydrogen phosphate and the like.

[0085] Examples of the binder include methylcellulose, ethylcellulose, gum arabic, hydroxypropylmethylcellulose, hydroxypropylcellulose and the like.

[0086] Examples of the disintegrant include low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, sodium carboxymethyl starch, crospovidone and the like.

[0087] Examples of lubricants include talc, silicon dioxide, magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol and the like.

[0088] Examples of the colorant include ferric oxide, yellow ferric oxide, magenta, β-carotene, titanium oxide, riboflavin sodium phosphate, yellow aluminum lake, cochineal and the like.

[0089] Examples of flavoring agents include cocoa powder, ascorbic acid, tartaric acid, peppermint oil, borneol, cinnamon powder and the like.

[0090] For the production of injections, the injections can be produced by (i) adding pH regulators, buffers, suspending agents, solubilizers, stabilizers, isotonic agents, preservatives, etc. to the main components as needed, and (ii) preparing intravenous injections, subcutaneous injections, or intramuscular injections or intravenous drips by ordinary methods. In this case, the injections can also be freeze-dried by ordinary methods as needed.

[0091] Examples of the pH adjuster and buffer include hydrochloric acid, sodium carbonate, sodium bicarbonate, citric acid, sodium citrate, sodium dihydrogen citrate, glycine, phosphoric acid, sodium dihydrogen phosphate, sodium monohydrogen phosphate, sodium hydroxide, acetic acid, sodium acetate, meglumine and the like.

[0092] Examples of suspending agents include sodium alginate, sucrose fatty acid esters, polysorbate 80, gum arabic, tragacanth powder, polyoxyethylene sorbitan monolaurate and the like.

[0093] Examples of the solubilizing agent include polyoxyethylene hydrogenated castor oil, polysorbate 80, niacinamide, polyoxyethylene sorbitan monolaurate, glycerol fatty acid esters, polyethylene glycol, propylene glycol, benzyl benzoate, ethanol, triethanolamine and the like.

[0094] Examples of the stabilizer include sodium sulfite, sodium metasulfite, and the like.

[0095] Examples of isotonic agents include glucose, mannitol, sorbitol, and the like.

[0096] Examples of the preservative include methyl paraoxybenzoate, ethyl paraoxybenzoate, sorbic acid, phenol, cresol, chlorocresol and the like.

[0097] In the pharmaceutical composition for treating Parkinson's disease disclosed herein, the dosage of compound (I) or its pharmaceutically acceptable salt is different according to the severity of symptoms, the age, sex, weight and sensitivity difference of the patient, the method of administration, the timing of administration and the type of pharmaceutical preparation. In the case of oral administration to an adult (weight 60kg), usually 100 μg to 5g of compound (I) or its pharmaceutically acceptable salt is administered in a single dose or several separate doses per day, 300 μg to 3g in one aspect, or 1 mg to 1g in another aspect. In the case of administration by injection, 30 μg to 1g of compound (I) or its pharmaceutically acceptable salt is administered in a single dose or several separate doses per day, 30 μg to 500 mg in one aspect, or 50 μg to 300 mg in another aspect. In one aspect, Compound (I) or a pharmaceutically acceptable salt thereof is orally administered once a day in an amount of 20 mg to 180 mg, 40 mg to 160 mg, 20 mg to 80 mg, 20 mg to 60 mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg, 160 mg or 180 mg.

[0098] The pharmaceutical composition for treating Parkinson's disease disclosed herein can be administered in combination with a dopamine replacement therapy. A dopamine replacement therapy refers to a drug for dopamine replacement therapy. Dopamine replacement therapy refers to a therapy that increases dopamine levels or a therapy that directly stimulates dopamine receptors. In other words, a dopamine replacement therapy can be a drug that increases dopamine levels or a drug that directly stimulates dopamine receptors. For example, a dopamine replacement therapy can be at least one selected from the group consisting of a dopamine precursor, a dopa decarboxylase inhibitor, a catechol-O-methyltransferase (COMT) inhibitor, a monoamine oxidase (MAOB) inhibitor, a dopamine release promoter, or a dopamine agonist. For example, a dopamine precursor includes levodopa, etc. Examples of dopa decarboxylase inhibitors can be carbidopa, benserazide, etc. For example, a COMT inhibitor can be entacapone, etc. For example, a MAOB inhibitor can be safinamide, selegiline, rasagiline, etc. For example, a dopamine release promoter can be amantadine, etc. For example, the dopamine agonist may be cabergoline, bromocriptine, pergolide, talipexole, pramipexole, ropinirole, rotigotine, or apomorphine. These drugs may be in the form of pharmaceutically acceptable salts.

[0099] The dopamine replacement therapy agent in this disclosure can be one or two or more combinations.The example of the combination of two or more dopamine replacement therapy agents includes the combined use of dopamine precursors and dopa decarboxylase inhibitors (for example, the combined use of levodopa and carbidopa, the combined use of levodopa and benserazide), the combined use of dopamine precursors, dopa decarboxylase inhibitors and COMT inhibitors (for example, the combined use of levodopa, carbidopa and entacapone), the combined use of dopamine precursors and dopamine agonists (for example, the combined use of levodopa and talipexol, the combined use of levodopa and cabergoline and the combined use of levodopa and ropinirole), the combined use of dopamine precursors and MAOB inhibitors (for example, the combined use of levodopa and selegiline) etc. In one aspect, dopamine replacement therapy agents contain levodopa.Dopamine replacement therapy agents can be single levodopa or other one or two or more medicines used with dopamine replacement therapy.

[0100] Dopamine replacement therapy agents and their dosages can be determined by referring to clinical guidelines for Parkinson's disease, such as "Parkinson's Disease Diagnosis and Treatment Guidelines 2018 (Parkinson Byo Shiryo Gaidorain 2018)" supervised by the Japan Neurological Society (Medical Shoin).

[0101] For example, the single drug dose of levodopa is different according to the severity of symptom, age, sex, body weight and sensitivity difference of patient, application method, application time and the kind of pharmaceutical preparation.In the case of oral administration to adult (body weight 60kg), levodopa is usually applied with the amount of 200mg to 600mg every day with single dose or several separated dosages, the amount is gradually increased with the amount of 200mg to 400mg every day for every 2 to 3 days, and after 2 to 4 weeks, levodopa is applied with the amount of 2000mg to 3600mg every day, as maintenance dose.The dosage of the combination drug of levodopa / carbidopa (mass ratio 100:10) is different according to the severity of symptom, age, sex, body weight and sensitivity difference of patient, application method, application time and the kind of pharmaceutical preparation. In the case of oral administration to an adult (weight 60kg), the combination drug is usually administered in a single dose or several divided doses in the following amounts: 100mg to 300mg per day in terms of levodopa, the amount in terms of levodopa is increased by 100mg to 125mg per day every day or every other day, and after 1 to 2 weeks, the combination drug is administered in the following amounts: 500mg to 1000mg per day in terms of levodopa as a maintenance dose. The dosage of the combination drug of levodopa / carbidopa (mass ratio 100:25) varies according to the severity of the symptoms, the age, sex, weight and sensitivity differences of the patient, the method of administration, the time of administration and the type of the pharmaceutical preparation. In the case of oral administration to an adult (60 kg in weight), the combination drug is usually administered in several divided doses in the following amount: 200 mg to 300 mg per day in terms of levodopa, the amount is increased by 100 mg to 200 mg per day in terms of levodopa every day or every other day as needed, and the combination drug is administered in the following amount: 400 mg to 1600 mg per day in terms of levodopa as the final maintenance dose. In the case of intrajejunal administration through the nose or intrajejunal administration through the stomach, the combination drug is administered in the morning in the amount of 100 mg to 200 mg in terms of levodopa over 10 to 30 minutes, and then continues to be administered in the amount of 40 mg to 120 mg per hour in terms of levodopa, and an additional amount of 10 mg to 40 mg per dose in terms of levodopa may be administered as needed, so that the maximum duration of administration is 16 hours per day, and the total daily dose does not exceed 2000 mg in terms of levodopa. The dosage of the combination drug of levodopa / benserazide (mass ratio 100:25) varies depending on the severity of symptoms, age, sex, weight and sensitivity difference of the patient, administration method, administration time and kind of drug preparation.In the case of oral administration to an adult (body weight 60kg), the combination drug is usually administered in a single dose or several separate doses: in levodopa, 100mg to 300mg per day, the amount is gradually increased with 100mg to 200mg per day every 2 to 3 days, and after 1 to 3 weeks, the combination drug is administered in the following amount: 300mg to 600mg per day as a maintenance dose. The dosage of the combination drug of levodopa / carbidopa / entacapone is different according to the severity of the symptoms, the age, sex, body weight and sensitivity differences of the patient, the method of administration, the time of administration and the kind of the pharmaceutical preparation. In the case of oral administration to an adult (body weight 60kg), the combination drug is usually administered in 50mg to 200mg amount in levodopa several times a day, so that in levodopa, the daily total amount does not exceed 1500mg, in total carbidopa, the daily total amount does not exceed 300mg, in entacapone, the daily total amount does not exceed 1600mg, and the dosage number does not exceed eight times a day.

[0102] In the present disclosure, the form of administration of the drug to be used in the case of a combination of compound (I) or a pharmaceutically acceptable salt thereof with a dopamine replacement therapeutic agent is not particularly limited, as long as the compound (I) or a pharmaceutically acceptable salt thereof is administered in combination with a dopamine replacement therapeutic agent. For example, compound (I) or a pharmaceutically acceptable salt thereof is administered to a patient simultaneously, separately, continuously or at certain time intervals with a dopamine replacement therapeutic agent. As used herein, the term "simultaneously" means that each component is administered in the same time period or at the same time in a strict sense, or is administered by the same route of administration. The term also means that there is no obvious time interval between the administration of each component, so that each component can exert the desired effect. The term "separate" means that each component is administered at different time intervals or administration frequencies, or by different routes of administration. The term "continuously" means that each component is administered in the same or different routes of administration, in any order within a certain period of time. The term "at certain time intervals" means that each component is administered at certain time intervals by the same or different routes of administration. Compound (I) or a pharmaceutically acceptable salt thereof and the dopamine replacement therapeutic agent may be administered as the same preparation or may be administered as different preparations.

[0103] The patient to be treated in the present disclosure is a patient suffering from Parkinson's disease, such as a patient suffering from Parkinson's disease with motor symptoms and / or a patient suffering from Parkinson's disease with motor complications. Examples of motor symptoms include tremor, bradykinesia, rigidity (muscle stiffness), postural deformity, etc.

[0104] The pharmaceutical compositions of the present disclosure do not worsen or affect motor complications associated with the progression of Parkinson's disease. Examples of motor complications include loss of efficacy, dyskinesia, and dystonia. In one aspect, the motor complication is dyskinesia.

[0105] If the pharmaceutical composition of the present disclosure is administered in combination with a dopamine replacement therapeutic agent such as levodopa, reducing the dose of the dopamine replacement therapeutic agent prevents the worsening of motor complications associated with the progression of Parkinson's disease or the impact on motor complications, while exhibiting the same or greater therapeutic effect on motor symptoms than when the dose of the dopamine replacement therapeutic agent is not reduced.

[0106] Examples

[0107] Pharmacological test cases

[0108] Using Parkinson's disease model animals produced by administration of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the therapeutic effect of compound (I) on Parkinson's disease was examined.

[0109] Test Example 1: Therapeutic effect of compound (I) alone

[0110] MPTP was administered to male cynomolgus monkeys aged 4 to 5 years to produce a Parkinson's disease model. MPTP was administered to animals with neurological deficit scores (NDSs, Schneider et al., "Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptomonset and / or duration of symptoms", Brain Res., 2003, 990: 38-44.) less than 25.

[0111] Eight Parkinson's disease model cynomolgus monkeys were randomly assigned to 5 groups with approximately equal means and variances in Parkinson's disease behavior assessment (tremor score) and body weight. In the subsequent 2nd, 3rd, 4th and 5th cycles, the animals were crossed over to receive other treatments. A washout period of 1 week or more was set between each cycle.

[0112] By the end of the study, each animal had received all five of the following treatments. Istradefylline is an adenosine A 2AA receptor antagonist approved in the United States and Japan as a drug for improving the disappearance of drug efficacy in Parkinson's disease treated with a preparation containing levodopa (Patent Document 4). An aqueous solution containing 0.43% (w / v) methylcellulose 400, 10% (v / v) dimethyl sulfoxide (DMSO) and 4.5% (w / v) Cremophor (R) was used as a vehicle.

[0113] [Table 1]

[0114] Group Administered substances Dosage (mg / kg) G1 vehicle - G2 Compound (I) low dose 5 G3 Medium dose of compound (I) 15 G4 High dose of compound (I) 50 G5 Istradefylline 60

[0115] The NDS of the monkeys was evaluated before administration and 1 hour, 4 hours and 24 hours after the test substance was administered. The evaluation items were as follows. The behavioral evaluation was performed in a blind manner. The NDS of each group was compared using the Steel test. A p value of less than 0.05 was considered statistically significant.

[0116] Subgroup 1: General behavior (0-32)

[0117] 1.1a Appetite

[0118] 0: Normal

[0119] 1: Up to 30% of food left

[0120] 2: Up to 65% of food left

[0121] 3: More than 65% of food is left

[0122] 1.1b Response to food provided

[0123] 0: Responds to food offered

[0124] 1: Erratic response to food provided

[0125] 2: Little to no interest in food offered

[0126] 1.2 Overall activity

[0127] 0: Normal

[0128] 1: Mild hypokinesia; decreased voluntary movements

[0129] 2: Moderate motor impairment; insufficient voluntary movement

[0130] 3: Severe motor impairment; no voluntary movements; tends to stay in one place

[0131] 1.3 Appearance

[0132] 0: Normal

[0133] 1: Mild, significantly reduced self-maintenance

[0134] 2: Moderate reduction in self-maintenance

[0135] 3: Severe lack of self-maintenance

[0136] 1.4 Posture

[0137] 0: Normal

[0138] 1: The body is slightly bent or leaning forward

[0139] 2: The body is moderately bent or leaning forward; the head and torso are almost parallel to the cage floor

[0140] 3: The body is severely bent or leaning forward; the head is lowered to the feet

[0141] 1.5 Balance

[0142] 0: Normal

[0143] 1: Mild loss of ability to stand up or move

[0144] 2: Moderate loss of standing or movement; sometimes falls or braces oneself to prevent falls

[0145] 3: Severe loss of balance; fall

[0146] 1.6 Climbing

[0147] 0: The climb is observed to start and execute without delay

[0148] 1: Mild impairment of climbing ability and ability to support body weight

[0149] 2: Moderately impaired ability to climb and support body weight; prone to slipping

[0150] 3: Unable to perform any climbing behavior

[0151] 1.7 Tremor

[0152] 0: None

[0153] 1: Mild and intermittent

[0154] 2: Mild and persistent or moderate and intermittent

[0155] 3: Moderate / severe and persistent

[0156] 1.8 Stiffness in Action

[0157] 0: None

[0158] 1: Sometimes stiffness, lasting for a short period of time

[0159] 2: Stiffness sometimes lasts for extended periods of time, or stiffness frequently lasts for brief periods of time

[0160] 3: Prolonged and frequent stiffness

[0161] 1.9 Facial Expressions

[0162] 0: Normal

[0163] 1: Mild lack of expression

[0164] 2: Lack of medium expression

[0165] 3: Severe loss of expression (like a mask)

[0166] 1.10 Defensive Response

[0167] 0: Normal

[0168] 1: Mildly, markedly reduced or slow in response, but can be stimulated to respond

[0169] 2: Moderately weakened response; facial expression can be produced, but the body does not react

[0170] 3: Little to no response

[0171] Subgroup 2: Specific motor function (0-21)

[0172] 2.1a Upper limb exercise

[0173] 0: Normal

[0174] 1: Significant reduction in upper limb use

[0175] 2: Moderate reduction in upper limb use

[0176] 3: Severe reduction in upper limb use

[0177] 2.1b Lower limb exercise

[0178] 0: Normal

[0179] 1: Significant reduction in the use of lower limbs

[0180] 2: Moderate reduction in lower extremity use

[0181] 3: Severe reduction in the use of lower limbs

[0182] 2.2a Upper limb range of motion

[0183] 0: Normal

[0184] 1: Slightly reduced, but almost fully extended

[0185] 2: Moderately reduced range of motion, some difficulty using; exhibits pronounced flexion at rest

[0186] 3: Severely reduced; limbs are in a flexed position at rest

[0187] 2.2b Lower limb range of motion

[0188] 0: Normal

[0189] 1: Slightly reduced, but almost fully extended

[0190] 2: Moderately reduced range of motion, some difficulty using; exhibits pronounced flexion at rest

[0191] 3: Severely reduced; limbs are in a flexed position at rest

[0192] 2.3 Fine Motor Skills

[0193] 0: Normal

[0194] 1: Apparently clumsy ability to grasp food or rewards; able to grasp food; occasionally drops food

[0195] 2: Moderately reduced ability to grasp and handle food; uses both hands to bring food to mouth; frequently drops food

[0196] 3: Cannot hold, hold, or manipulate food; can approach food directly with mouth

[0197] 2.4 Eating

[0198] 0: Normal

[0199] 1: Chewing is mildly slow and / or interrupted occasionally

[0200] 2: Chewing mildly slowly with frequent interruptions, or chewing moderately slowly with occasional interruptions

[0201] 3. Inability to feed oneself effectively

[0202] 2.5 Blink rate (number of blinks in 20 seconds)

[0203] 0: Normal (blink 6 times or more)

[0204] 1: Slightly reduced (blink 4-5 times)

[0205] 2: Moderate decrease (blink 2-3 times)

[0206] 3: Severely reduced (0-1 blinks)

[0207] The total scores of NDS (total scores of subgroup 1 and subgroup 2) are shown in Tables 2 and Figure 1In the medium and high doses of Compound (I) treated groups (G3 and G4) and the istradefylline treated group (G5), the total score 4 hours after each administration was significantly lower than that in the vehicle treated group (G1 vs. G3: p=0.0215; G1 vs. G4: p=0.0135; G1 vs. G5: p=0.0048).

[0208] [Table 2]

[0209]

[0210] *: p<0.05 relative to G1, **: p<0.01 relative to G1

[0211] The general behavior scores are shown in Table 3 and Figure 2 In the istradefylline-treated group (G5), the general behavior score 4 hours after administration was significantly lower than that of the vehicle-treated group (G1 vs. G5: p=0.0327).

[0212] [Table 3]

[0213]

[0214] *: p<0.05 compared with G1

[0215] The scores of specific motor functions are shown in Table 4 and Figure 3 In the medium and high doses of compound (I) treated groups (G3 and G4) and the istradefylline treated group (G5), the scores of specific motor function 4 hours after each administration were significantly lower than those in the vehicle treated group (G1 vs. G3: p=0.0089; G1 vs. G4: p=0.0025; G1 vs. G5: p=0.0037).

[0216] [Table 4]

[0217]

[0218] **: p<0.01 relative to G1

[0219] Tremor scores are shown in Table 5 and Figure 4 In the high-dose Compound (I)-treated group (G4), the tremor scores at 4 and 24 hours after administration were significantly lower as compared with the vehicle-treated group (G1 vs. G4 after 4 hours: p=0.0024; G1 vs. G4 after 24 hours: p=0.0317).

[0220] [Table 5]

[0221]

[0222] *: p<0.05 relative to G1, **: p<0.01 relative to G1

[0223] Test Example 2: Therapeutic effect of combined administration of compound (I) and levodopa

[0224] In the same manner as in Test Example 1, a Parkinson's disease model cynomolgus monkey was provided, and the therapeutic effect of combined administration of compound (I) and levodopa was examined.

[0225] By the end of the study, each animal had received all five of the following treatments: An aqueous solution containing 0.43% (w / v) methylcellulose 400, 10% (v / v) dimethyl sulfoxide (DMSO) and 4.5% (w / v) Cremophor(R) was used as a vehicle.

[0226] [Table 6]

[0227] Group Administered substances and dosage G1 vehicle G2 Levodopa 10 mg / kg G3 Levodopa 5 mg / kg G4 Levodopa 5mg / kg + compound (I) 50mg / kg G5 Levodopa 5mg / kg + compound (I) 25mg / kg

[0228] The NDS of the monkeys was evaluated before administration and 1 hour, 4 hours and 24 hours after administration of the test substance. The evaluation items and evaluation method were the same as those in Test Example 1.

[0229] The total scores of NDS are shown in Table 7 and Figure 5 In the levodopa-treated group (G2 to G3) and the levodopa+compound (I)-treated group (G4 to G5), the total score 1 hour after each administration was significantly lower than that in the vehicle-treated group (G1 vs. G2: p=0.0049; G1 vs. G3: p=0.0293, G1 vs. G4: p=0.0186, G1 vs. G5: p=0.0048). In the levodopa 10 mg / kg-treated group (G2) and the levodopa+compound (I)-treated group (G4 to G5), the total score 4 hours after each administration was significantly lower than that in the vehicle-treated group (G1 vs. G2: p=0.0154, G1 vs. G4: p=0.0033, G1 vs. G5: p=0.0081).

[0230] [Table 7]

[0231]

[0232] *: p<0.05 relative to G1, **: p<0.01 relative to G1

[0233] The general behavior scores are shown in Table 8 and Figure 6In the levodopa-treated group (G2 to G3) and the levodopa+compound (I)-treated group (G4 to G5), the general behavior score 1 hour after each administration was significantly lower than that of the vehicle-treated group (G1 vs. G2: p=0.0128, G1 vs. G3: p=0.0127, G1 vs. G4: p=0.0309, G1 vs. G5 p=0.0051). In the levodopa 10 mg / kg-treated group (G2) and the levodopa+compound (I)-treated group (G4 to G5), the general behavior score 4 hours after each administration was significantly lower than that of the vehicle-treated group (G1 vs. G2: p=0.0098, G1 vs. G4: p=0.0027, G1 vs. G5: p=0.0084).

[0234] [Table 8]

[0235]

[0236] *: p<0.05 relative to G1, **: p<0.01 relative to G1

[0237] The scores for specific motor functions are shown in Table 9 and Figure 7 In the levodopa-treated group (G2 to G3) and the levodopa+compound (I)-treated group (G4 to G5), the specific motor function score was significantly lower than that of the vehicle-treated group 1 hour after each administration (G1 vs. G2: p=0.0099, G1 vs. G3: p=0.0366, G1 vs. G4: p=0.0177, G1 vs. G5 p=0.0175). In the levodopa+compound (I)-treated group (G4 to G5), the specific motor function score was significantly lower than that of the vehicle-treated group 4 hours after each administration (G1 vs. G4: p=0.0080, G1 vs. G5: p=0.0366).

[0238] [Table 9]

[0239]

[0240] *: p<0.05 relative to G1, **: p<0.01 relative to G1

[0241] Tremor scores are shown in Table 10 and Figure 8In the levodopa 10 mg / kg treatment group (G2) and the levodopa + compound (I) treatment group (G4 to G5), the tremor score 1 hour after each administration was significantly lower than that in the vehicle-treated group (G1 vs. G2: p=0.0287, G1 vs. G4: p=0.0103, G1 vs. G5: p=0.0103). In the levodopa 10 mg / kg treatment group (G2) and the levodopa + compound (I) treatment group (G4 to G5), the tremor score 4 hours after each administration was significantly lower than that in the vehicle-treated group (G1 vs. G2: p=0.0287, G1 vs. G4: p=0.0103, G1 vs. G5: p=0.0103).

[0242] [Table 10]

[0243]

[0244] *: p<0.05 compared with G1

[0245] Test Example 3: Effect of Compound (I) on Levodopa-induced Dyskinesia

[0246] A levodopa / carbidopa mixture (containing levodopa 80 mg / kg and carbidopa 20 mg / kg, solution volume 5 mL / kg) was orally administered continuously for 8 days to a 6- to 7-year-old Parkinson's disease model cynomolgus monkey prepared in the same manner as in Test Example 1 to provide a levodopa-induced dyskinesia model cynomolgus monkey. The induction of dyskinesia was determined based on the "dyskinesia score" according to the following behavioral evaluation items in the following home cage activity test, and animals with a dyskinesia score of 1 or more on the 7th day of repeated administration of the levodopa / carbidopa mixture were used.

[0247] Home cage activity corresponding to dyskinesia scores

[0248] 0: Normal home cage activity (exploratory or resting behavior, able to drink water, playing in front of a mirror or in a cage, climbing a wall).

[0249] 1: Some interference with normal activities, but able to climb walls.

[0250] 2: Occasionally exploratory behavior in the cage, some stereotyped behavior

[0251] 3: Almost incapable of normal movement, does not climb walls, obvious stereotyped behavior

[0252] 4: Lack of normal cage activity, lack of normal exploratory behavior and movement, severe stereotypic behavior

[0253] Seven levodopa-induced dyskinesia model cynomolgus monkeys were randomly assigned to four groups with approximately equal means and variances in body weight. The animals were then crossed over to receive other treatments in the subsequent cycles 2, 3, and 4. A washout period of 1 week or more was set between cycles.

[0254] One of the seven became unable to stand on day 8 of repeat administration of the levodopa / carbidopa mixture in cycle 3 due to dyskinesia and was therefore excluded from the evaluations in cycles 3 and 4.

[0255] By the end of the study, each animal had received all four of the following treatments. Each substance was administered 1 hour after administration on the 8th day of repeated administration of the levodopa / carbidopa mixture. An aqueous solution containing 0.43% (w / v) methylcellulose 400, 10% (v / v) dimethyl sulfoxide (DMSO) and 4.5% (w / v) Cremophor (R) was used as a vehicle.

[0256] [Table 11]

[0257] Group Administered substances and dosage G1 vehicle G2 Compound (I) 25 mg / kg G3 Compound (I) 50 mg / kg G4 Istradefylline 60 mg / kg

[0258] Animals were assessed for dyskinesia scores before administration and 1 hour, 4 hours, and 24 hours after test substance administration. Behavioral assessment was performed in a blinded manner. The dyskinesia scores of each group were compared using the Steel test. P values ​​less than 0.05 were considered statistically significant.

[0259] The dyskinesia scores are shown in Tables 12 and Fig. 9 No statistically significant differences were observed among the four groups at any measurement time. However, the mean value of the dyskinesia score of the compound (I)-treated group (G3) at 4 hours after administration was lower than that of the vehicle-treated group (G1) and the istradefylline-treated group (G4) at the same measurement time.

[0260] [Table 12]

[0261] Group Before application 1 hour 4 hours 24 hours G1 1.9±0.1 1.9±0.1 1.9±0.1 1.9±0.1 G2 1.7±0.2 2.0±0.0 1.6±0.2 2.0±0.0 G3 1.7±0.2 1.8±0.2 1.3±0.2 1.8±0.2 G4 1.7±0.2 1.8±0.2 1.8±0.2 1.8±0.2

Claims

1. A pharmaceutical composition for treating Parkinson's disease, comprising N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfonamide represented by formula (I): or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition according to claim 1, wherein the composition is administered in combination with a dopamine replacement therapeutic agent.

3. The pharmaceutical composition according to claim 2, wherein the dopamine replacement therapeutic agent comprises levodopa.

4. The pharmaceutical composition according to any one of claims 1 to 3, for use in treating motor symptoms of Parkinson's disease.